HK Stock Market Move | U-PRESID China (00220) closes up over 6%, annual net profit exceeds 2 billion, Goldman Sachs says adjusted net profit exceeds expectations.
Unify Enterprise China (00220) rose more than 6% in the final trading session, rising 5.6% as of the time of this report, to 8.49 Hong Kong dollars, with a turnover of 157 million Hong Kong dollars.
U-PRESID CHINA (00220) surged more than 6% in the final trading session, rising by 5.6% to HK$8.49 at the time of writing, with a turnover of HK$157 million.
In terms of news, U-PRESID CHINA released its annual performance report, stating that the group's revenue reached RMB 31.714 billion in 2025, a year-on-year increase of 4.6%; net profit after tax reached RMB 2.05 billion, a year-on-year increase of 10.9%. Goldman Sachs stated that net profit was lower than the bank's and market consensus, mainly due to a one-time impairment of investment. Excluding this impact, adjusted net profit increased by 17.6% annually to RMB 2.174 billion, about 2% higher than the bank's expectations.
Guoyuan (Hong Kong) pointed out that the company achieved mid-single-digit growth in overall sales in January and February, looking ahead to 2026, we expect the company to continue its steady operation. After the subsiding of factors such as the delivery war, we will focus on whether the industry competition stabilizes, and thus drive the recovery of the beverage business. The current dividend yield exceeds 6.5%, which is worth paying attention to.
Related Articles

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.

CICC: Maintain "Buy" rating on HANSOH PHARMA (03692), raise target price to HK$46.41
Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.

CICC: Maintain "Buy" rating on HANSOH PHARMA (03692), raise target price to HK$46.41

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


